Suppr超能文献

华法林使用后国际标准化比值高于治疗范围且无出血的管理:维生素K给药的评估(SUPRA-WAR-K研究)

Management of Supratherapeutic International Normalized Ratio without Bleeding after Warfarin Use: An Evaluation of Vitamin K Administration (SUPRA-WAR-K Study).

作者信息

Tai Claire, Wu Hilary, San Cindy, Chua Doson

机构信息

BSc(Pharm), ACPR, is a Clinical Pharmacist with Fraser Health, Surrey, British Columbia.

BSc(Pharm), ACPR, PharmD, is a Clinical Pharmacist with Providence Health Care, Vancouver, British Columbia.

出版信息

Can J Hosp Pharm. 2017 May-Jun;70(3):207-214. doi: 10.4212/cjhp.v70i3.1660. Epub 2017 Jun 30.

Abstract

BACKGROUND

For patients with supratherapeutic international normalized ratio (INR) and no evidence of bleeding, the 2012 guidelines of the American College of Chest Physicians discourage administration of vitamin K. At the study hospital, it was observed that vitamin K was frequently prescribed for patients with INR of 4.5 or higher and no bleeding.

OBJECTIVES

To compare efficacy and safety outcomes between holding warfarin alone and holding warfarin with administration of vitamin K and to compare these outcomes among various doses and routes of vitamin K administration in non-critical care inpatients experiencing supratherapeutic INR without evidence of bleeding.

METHODS

This single-centre retrospective chart review involved noncritical care inpatients with supratherapeutic INR (4.5-8.9) without evidence of bleeding. The primary outcomes were the change in INR 1 day after implementation of supratherapeutic INR management and the time to reach INR less than 3.0. The secondary outcomes were length of stay, frequency of warfarin resistance, incidence and duration of bridging anticoagulation, incidence of thromboembolism and major bleeding, and death.

RESULTS

Regardless of vitamin K dose, the administration of vitamin K combined with holding warfarin, relative to holding warfarin alone, was associated with a greater INR decrease 1 day after the intervention (mean ± standard deviation -3.2 ± 1.9 versus -0.9 ± 1.0, < 0.001) and a shorter time to reach INR below 3.0 (1.9 ± 1.0 days versus 2.6 ± 1.4 days, = 0.003). No statistically significant differences in any other outcomes were observed.

CONCLUSIONS

In hospitalized non-critical care patients with INR between 4.5 and 8.9 without evidence of bleeding, the combination of holding warfarin and administering vitamin K was associated with greater and faster decreases in INR than holding warfarin alone. No significant differences were found in clinically important outcomes. The practice of administering vitamin K in this population warrants further study and re-evaluation.

摘要

背景

对于国际标准化比值(INR)高于治疗范围且无出血迹象的患者,美国胸科医师学会2012年指南不建议使用维生素K。在研究医院中,观察到经常为INR为4.5或更高且无出血的患者开具维生素K。

目的

比较单独停用华法林与停用华法林并使用维生素K之间的疗效和安全性结果,并比较在无出血迹象的非重症监护住院患者中,不同剂量和途径使用维生素K的这些结果。

方法

这项单中心回顾性病历审查涉及INR高于治疗范围(4.5 - 8.9)且无出血迹象的非重症监护住院患者。主要结局是实施高于治疗范围的INR管理1天后INR的变化以及达到INR小于3.0的时间。次要结局包括住院时间、华法林抵抗频率、桥接抗凝的发生率和持续时间、血栓栓塞和大出血的发生率以及死亡率。

结果

无论维生素K剂量如何,与单独停用华法林相比,停用华法林并使用维生素K在干预1天后INR下降幅度更大(均值±标准差 -3.2±1.9对 -0.9±1.0,P<0.001),且达到INR低于3.0的时间更短(1.9±1.0天对2.6±1.4天,P = 0.003)。在任何其他结局方面未观察到统计学显著差异。

结论

在INR为4.5至8.9且无出血迹象的住院非重症监护患者中,停用华法林并使用维生素K与单独停用华法林相比,INR下降幅度更大且更快。在临床重要结局方面未发现显著差异。在该人群中使用维生素K的做法值得进一步研究和重新评估。

相似文献

2
Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio > 10.
J Thromb Haemost. 2020 May;18(5):1133-1140. doi: 10.1111/jth.14772. Epub 2020 Mar 30.
4
A retrospective evaluation of vitamin K1 therapy to reverse the anticoagulant effect of warfarin.
Pharmacotherapy. 2003 Oct;23(10):1245-50. doi: 10.1592/phco.23.12.1245.32701.
6
Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases.
J Thromb Thrombolysis. 2009 Apr;27(3):340-7. doi: 10.1007/s11239-008-0211-4. Epub 2008 Mar 13.
9
Supra-therapeutic Anticoagulation with Warfarin: A Cross-sectional Study.
Curr Drug Saf. 2023;18(1):23-30. doi: 10.2174/1574886317666220429103847.
10
Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10.
Thromb Res. 2004;113(3-4):205-9. doi: 10.1016/j.thromres.2004.03.004.

本文引用的文献

3
In-hospital management of atrial fibrillation: the CHADS₂ score predicts increased cost.
Can J Cardiol. 2011 Jul-Aug;27(4):506-13. doi: 10.1016/j.cjca.2011.01.002. Epub 2011 May 4.
5
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial.
Ann Intern Med. 2009 Mar 3;150(5):293-300. doi: 10.7326/0003-4819-150-5-200903030-00005.
7
Coagulation abnormalities in critically ill patients.
Crit Care. 2006;10(4):222. doi: 10.1186/cc4975.
8
A review of warfarin dosing and monitoring.
Proc (Bayl Univ Med Cent). 2001 Jul;14(3):305-6. doi: 10.1080/08998280.2001.11927781.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验